List of Excipients in Branded Drug AMITIZA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	AMITIZA	lubiprostone	16590-622	FERRIC OXIDE RED
STAT RX USA LLC	AMITIZA	lubiprostone	16590-622	GELATIN
STAT RX USA LLC	AMITIZA	lubiprostone	16590-622	MEDIUM-CHAIN TRIGLYCERIDES
STAT RX USA LLC	AMITIZA	lubiprostone	16590-622	SORBITOL
STAT RX USA LLC	AMITIZA	lubiprostone	16590-622	TITANIUM DIOXIDE

Amitiza Excipient Strategy and Commercial Opportunities for Lubiprostone

Last updated: November 8, 2026

Amitiza is the branded lubiprostone product, an oral softgel approved for chronic idiopathic constipation, irritable bowel syndrome with constipation in adult women, and opioid-induced constipation in adults with chronic non-cancer pain. Its core excipient system is simple: gelatin, medium-chain triglycerides, sorbitol, purified water, and colorant. The commercial opportunity is therefore less likely to come from basic excipient substitution and more likely to come from improved dosage forms, patient tolerability, age-specific products, manufacturing efficiency, and differentiated 505(b)(2) or generic strategies.[1]

What excipients are used in Amitiza capsules?

Amitiza is supplied as a liquid-filled soft gelatin capsule. The labeled inactive ingredients are gelatin, medium-chain triglycerides, sorbitol, purified water, and FD&C Red No. 40.[1]

Product attribute	Amitiza specification
Active ingredient	Lubiprostone
Strengths	8 mcg and 24 mcg
Dosage form	Liquid-filled soft gelatin capsule
Route	Oral
Principal fill vehicle	Medium-chain triglycerides
Humectant or sweetening excipient	Sorbitol
Capsule shell	Gelatin
Colorant	FD&C Red No. 40
FDA application	NDA 021908
Main indications	CIC, IBS-C, and OIC

The formulation uses a lipid vehicle rather than a conventional compressed tablet matrix. That approach is consistent with lubiprostone's very low systemic exposure and low dose. A liquid fill permits uniform dispersion of a microgram-level active ingredient and supports softgel encapsulation at both 8 mcg and 24 mcg strengths.

What is the role of each Amitiza excipient?

Medium-chain triglycerides provide the liquid vehicle for lubiprostone and support fill uniformity. They also offer a commercially established softgel excipient platform with broad manufacturing availability.

Gelatin forms the capsule shell. It provides mechanical strength, oxygen and moisture protection, and rapid disintegration in gastrointestinal fluid. The use of gelatin limits the product's suitability for vegetarian, vegan, and certain religious-diet segments.

Sorbitol acts primarily as a plasticizing and moisture-management component in the capsule shell or formulation system. It can affect shell flexibility, water activity, dissolution, and long-term stability. Sorbitol may also contribute to gastrointestinal intolerance in sensitive patients, although the clinical impact depends on the total formulation quantity and patient exposure.

Purified water is used during manufacturing and remains part of the finished softgel system at controlled levels. Water content directly affects capsule brittleness, elasticity, dissolution, and microbial control.

FD&C Red No. 40 provides capsule coloration. A colorant-free or alternative-color product could address patients with colorant sensitivities and simplify market positioning, but it would require appropriate regulatory and product-quality support.

How does Amitiza’s excipient strategy affect commercial positioning?

Amitiza's excipient system supports reliable low-dose delivery but leaves several potential differentiation points.

Patient acceptability

The current gelatin shell excludes consumers seeking vegetarian or vegan products. A plant-based shell using hypromellose or modified starch could expand the addressable market. The substitute must preserve oxygen barrier performance, flexibility, sealing, rupture characteristics, dissolution, and stability.

A colorant-free capsule could target patients who avoid synthetic dyes. This change would have limited therapeutic differentiation but could support pharmacy and consumer-health positioning.

The oral softgel format may be difficult for patients with dysphagia. A liquid, sprinkle, orally disintegrating, or smaller-volume dosage form could improve administration in older adults and patients receiving chronic opioid therapy.

Tolerability

Lubiprostone commonly causes nausea and diarrhea, and the prescribing information recommends administration with food and water to reduce nausea.[1] Excipient selection cannot be expected to eliminate active-ingredient-related adverse events, but it may influence local gastrointestinal exposure, disintegration, and patient experience.

Replacing sorbitol or reducing polyol exposure may be relevant for patients with gastrointestinal sensitivity. The commercial value would depend on whether the reformulation produces a clinically meaningful tolerability benefit rather than only a theoretical excipient improvement.

Manufacturing robustness

Softgel production requires tight control of fill viscosity, shell moisture, seam integrity, drying conditions, and active-content uniformity. A formulation with alternative lipid vehicles, lower water activity, or improved fill rheology could reduce manufacturing losses and improve scale-up.

Those changes may also create intellectual-property opportunities around:

• Lubiprostone dispersion uniformity
• Capsule-shell composition
• Fill viscosity and encapsulation conditions
• Moisture control
• Dissolution performance
• Long-term stability
• Reduced oxidation or degradation
• Packaging compatibility

Manufacturing patents are most valuable when they produce measurable cost, quality, or stability advantages and are difficult to design around.

What formulations could compete with Amitiza?

The strongest formulation opportunities are products that preserve lubiprostone's low-dose performance while solving a specific administration or patient-segment problem.

Formulation concept	Target need	Regulatory route	Commercial potential
Vegetarian softgel	Avoidance of animal-derived gelatin	ANDA if therapeutically equivalent; 505(b)(2) if material differences exist	Moderate
Colorant-free softgel	Dye avoidance	ANDA or 505(b)(2) depending on differences	Limited to moderate
Smaller capsule	Dysphagia and geriatric use	ANDA or 505(b)(2)	Moderate
Oral liquid	Flexible dosing and swallowing support	Likely 505(b)(2)	Moderate to high
Powder or sprinkle formulation	Administration through soft food or feeding systems	Likely 505(b)(2)	High if technically feasible
Orally disintegrating dosage form	Convenience and swallowing support	Likely 505(b)(2)	Moderate
Modified-release formulation	Reduced nausea or dosing frequency	505(b)(2)	High development risk and potentially high value
Combination product	Constipation plus another gastrointestinal therapy	New drug application or 505(b)(2)	Selective

An oral liquid has the clearest age and administration rationale, but it also presents the greatest formulation risk. Lubiprostone's low dose must remain uniformly distributed throughout the container, maintain chemical stability, and support accurate dosing after repeated opening. Preservative selection, adsorption to packaging, and dose-device compatibility would be central development issues.

What patents protect Amitiza and lubiprostone formulations?

Lubiprostone's early patent estate centered on the active compound and pharmaceutical compositions rather than a broad, modern excipient platform. The key U.S. patent family associated with lubiprostone included U.S. Patent No. 6,583,174 and related patents covering prostaglandin derivatives and therapeutic use. These patents have reached or passed their ordinary U.S. patent-term endpoints based on their filing histories and statutory patent term rules.[2][3]

The practical protection profile has changed because:

1. Compound-level patent protection is no longer the primary barrier to U.S. generic entry.
2. Generic lubiprostone products have reached the U.S. market.
3. Any current competitive advantage must come from formulation, manufacturing, device, labeling, supply, or commercial execution.
4. A new excipient system may be patentable only if it produces a non-obvious technical result.

A formulation patent covering gelatin replacement alone may face design-around risk. A stronger claim set would combine the excipient system with measurable performance parameters such as dissolution, stability, capsule brittleness, active uniformity, or reduced degradation.

What formulations are most defensible against generic competition?

The strongest formulation claims generally cover a defined composition and a reproducible product attribute. Examples include:

• A specific lubiprostone concentration in a specified lipid vehicle
• A non-gelatin shell with defined polymer ratios and moisture content
• A capsule that meets a particular dissolution profile
• A formulation that maintains assay and impurity limits after accelerated storage
• A liquid product with a validated dose-uniformity range
• A delivery system compatible with a defined dosing device

Broad claims to "a pharmaceutical composition comprising lubiprostone and an excipient" are likely to face validity and design-around challenges because the active ingredient and many conventional excipients are established.

When does Amitiza lose exclusivity?

Amitiza's U.S. market exclusivity has already moved from originator protection to generic competition. FDA records identify the product as an approved prescription drug with generic lubiprostone competition, subject to the specific strength, dosage form, manufacturer, and approval status recorded in the Orange Book.[4]

The key commercial distinction is between:

• Compound and composition patents
• FDA orphan, pediatric, or other regulatory exclusivity
• Orange Book-listed patents
• Formulation or process patents
• Patent litigation settlements
• Actual ANDA approvals and commercial launches

Patent expiration does not automatically create immediate generic availability. Generic entry depends on ANDA approval, patent certifications, court orders, settlement terms, manufacturing readiness, and commercial launch decisions. For Amitiza, the existence of generic approvals means that a new commercial strategy must compete on cost, supply reliability, dosage-form differentiation, or targeted patient use.

What is the Orange Book status of Amitiza?

The Orange Book is the controlling FDA source for listed patents, therapeutic-equivalence evaluations, and approved strengths and dosage forms.[4] Amitiza's relevant Orange Book analysis should be performed at the product level because patent listings and generic approvals may vary by strength and dosage form.

For a commercial diligence review, the following fields are material:

Orange Book issue	Business implication
Listed patents	Determines certification and potential litigation exposure
Approved 8 mcg and 24 mcg strengths	Defines the conventional generic target
Softgel dosage form	Creates manufacturing and bioequivalence requirements
Therapeutic-equivalence codes	Indicates whether approved generics are substitutable
Patent delisting or expiration	Affects timing of additional ANDA activity
New formulation listing	May create a separate entry barrier if properly supported

An excipient change that remains within the same dosage form may be pursued through an ANDA if the product meets applicable sameness and bioequivalence requirements. A new liquid, sprinkle, or modified-release product generally presents a stronger case for a 505(b)(2) application.

Which companies are challenging or competing with Amitiza?

The competitive landscape includes the branded Amitiza product, generic lubiprostone suppliers, and competing prescription therapies for constipation.

Relevant prescription competitors include linaclotide, marketed as Linzess; plecanatide, marketed as Trulance; and prucalopride, marketed as Motegrity. Over-the-counter polyethylene glycol, stimulant laxatives, stool softeners, and magnesium-based products compete for the same constipation treatment budgets.

Product	Active ingredient	Primary competitive dimension
Amitiza	Lubiprostone	Secretagogue, oral softgel
Linzess	Linaclotide	Guanylate cyclase-C agonist
Trulance	Plecanatide	Guanylate cyclase-C agonist
Motegrity	Prucalopride	Selective 5-HT4 agonist
Generic lubiprostone	Lubiprostone	Price and formulary access
OTC laxatives	Multiple	Low cost and self-care access

Generic lubiprostone manufacturers can compete on acquisition cost, supply continuity, and pharmacy substitution. A reformulated product must demonstrate enough value to avoid direct price comparison with standard generic softgels.

What Paragraph IV and litigation risks affect lubiprostone?

Historically, generic applicants challenging branded products may file Paragraph IV certifications against listed patents under the Hatch-Waxman Act. Such certifications can trigger patent litigation before approval and can create a 30-month stay in some circumstances.[5]

For lubiprostone, the principal legal risk categories are:

• Paragraph IV challenges to listed composition or method-of-use patents
• Claims involving chronic idiopathic constipation, IBS-C, or OIC labeling
• Patent validity challenges based on obviousness or written description
• Infringement claims involving softgel composition or manufacturing
• Settlement agreements governing launch dates
• Regulatory disputes over labeling carve-outs and therapeutic equivalence

The value of a new excipient patent depends partly on whether an ANDA applicant would infringe it. A patent that claims only an optional excipient may have limited practical leverage. A patent that covers the required formulation architecture, manufacturing process, or product-performance specification may carry greater enforcement value.

How should companies develop an Amitiza excipient strategy?

A commercially disciplined strategy should prioritize one of three objectives.

1. Reduce cost

A generic manufacturer can evaluate alternative gelatin suppliers, lipid vehicles, shell plasticizers, colorants, and packaging systems. Cost savings must not compromise assay, dissolution, impurities, microbial quality, or capsule integrity.

2. Improve patient access

A vegetarian capsule, smaller capsule, colorant-free product, or liquid formulation can target patient groups poorly served by the conventional softgel. Pediatric development would require separate safety, dosing, and regulatory analysis because Amitiza's approved indications and age restrictions do not create an automatic pediatric opportunity.[1]

3. Build differentiated intellectual property

A differentiated product should generate patent claims around a defined technical effect. Useful data packages would include:

• Comparative dissolution
• Active uniformity
• Accelerated and long-term stability
• Capsule mechanical testing
• Moisture and oxygen transmission
• Impurity formation
• In-use stability
• Dose-delivery accuracy
• Human tolerability, where relevant

The preferred sequence is to identify the patient or manufacturing problem first, then select the excipient system. Starting with a commodity excipient substitution is less likely to produce durable value.

What generic launch scenarios exist for Amitiza?

Generic launch scenarios fall into three categories:

1. Standard softgel substitution, driven primarily by price and pharmacy interchangeability.
2. Multi-source generic competition, where supply reliability and contract manufacturing determine share.
3. Reformulated or differentiated entry, where a company seeks premium pricing through administration, dietary, tolerability, or device advantages.

The first scenario is the most established. The third offers more commercial upside but carries higher development, clinical, regulatory, and manufacturing risk.

How strong is the Amitiza patent estate?

The historical compound and composition estate provided the main period of originator protection. The current estate is less capable of blocking standard generic entry because the market has generic lubiprostone products and the principal early patents have reached their ordinary term endpoints.

A new product-specific excipient estate could still be valuable if it covers:

• A non-obvious formulation
• A difficult-to-replicate manufacturing process
• A clinically relevant administration advantage
• A device-formulation combination
• A stable liquid or sprinkle presentation
• A defined product-performance profile

Its strength would depend on claim scope, prosecution history, enforceability, and whether a generic applicant can design around the formulation without sacrificing product quality.

Key Takeaways

• Amitiza is a lubiprostone liquid-filled softgel containing gelatin, medium-chain triglycerides, sorbitol, purified water, and FD&C Red No. 40.
• Standard generic competition has reduced the value of compound-level exclusivity.
• The strongest commercial opportunities are vegetarian softgels, colorant-free products, smaller capsules, oral liquids, and sprinkle-compatible dosage forms.
• Excipient changes should be tied to measurable benefits in stability, manufacturability, dosing accuracy, or patient administration.
• A conventional excipient substitution is unlikely to create durable protection without a non-obvious technical result.
• An ANDA is the likely route for a therapeutically equivalent softgel; a materially different liquid, sprinkle, or modified-release product would more likely require a 505(b)(2) strategy.
• The principal commercial barriers are bioequivalence, dose uniformity, softgel manufacturing, stability, formulation IP, and generic price competition.

FAQs

Can Amitiza be reformulated without changing the active ingredient?

Yes. A reformulation can retain lubiprostone while changing the capsule shell, vehicle, colorant, package, or dosage form. The regulatory route depends on whether the product remains therapeutically equivalent to the approved softgel.

Is a vegetarian Amitiza capsule commercially attractive?

Potentially. A vegetarian capsule could address dietary and patient-preference restrictions, but its value would depend on pharmacy coverage, price premium, shell performance, and evidence that the formulation maintains equivalent quality and absorption.

Can sorbitol be removed from a lubiprostone formulation?

Potentially, but the change could affect shell flexibility, moisture balance, dissolution, and stability. A replacement would require comparative formulation and product-quality data.

Would a liquid lubiprostone product receive new exclusivity?

A liquid dosage form could support new formulation patents and potentially a separate FDA approval pathway, but it would not automatically receive meaningful regulatory exclusivity. Exclusivity would depend on the application type and the specific regulatory designation.

Does a new excipient create freedom from Amitiza patents?

No. Freedom to operate requires claim-by-claim analysis of active-ingredient, formulation, method-of-use, manufacturing, and device patents in each relevant jurisdiction.

References

1. U.S. Food and Drug Administration. (2023). Amitiza (lubiprostone) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation resources. https://www.uspto.gov/patents/laws/patent-term-calculator

3. U.S. Patent No. 6,583,174. (2003). Prostaglandin derivatives. United States Patent and Trademark Office. https://patents.google.com/patent/US6583174

4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2017). ANDA submissions: Content, format, and bioequivalence requirements. https://www.fda.gov/drugs/guidance-compliance-regulatory-information-guidances-drugs/abbreviated-new-drug-application-anda-process-enhancements-sections-505j-1-and-505j-2-federal-food